title: Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
abstract: Tamoxifen citrate (Tmx) was formulated in nanostructured lipid carrier system (NLC) using long chain solid lipids (LCSL) and oils (LCO) with the aim to target lymphatic system to improve its bioavailability in plasma and lymphnode (initial sites for metastasis) and reduce its drug associated toxicity. Tamoxifen loaded NLC (Tmx-NLC) was formulated using solvent diffusion technique. Preformulation studies comprised evaluation of drug-excipients compatibility. Solubility of Tmx was screened in LCSL and LCO, surfactants and co-surfactants to identify NLC components. Surfactant co-surfactant combinations were studied for their ability to stabilize the system. Tmx-NLC was physicochemically characterized by TEM, DSC, XRD, and FTIR studies. Drug-excipients chemical compatibility study facilitated anticipation of excipients induced oxidative degradation of Tmx. Suitable storage condition below 30°C could stabilize Tmx. Tmx-NLC with >90% entrapment efficiency and 215.60 ± 7.98 nm particle size were prepared and freeze dried. Freeze dried Tmx-NLC could withstand various gastrointestinal tract (GI) media (pH 1.2, pH 3.5, pH 4.5, pH 6.8, pH 7.4). Dissolution profile of Tmx-NLC in various media showed sustained release pattern irrespective of pH of medium. No significant change in characteristics of Tmx-NLC was observed after 3 months of accelerated stability studies.
authors.affiliation: Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai 400019, Maharashtra, India.
authors.forename: Harshad
authors.initials: H
authors.lastname: Shete
authors.forename: Vandana
authors.initials: V
authors.lastname: Patravale
mesh_terms: D002152:Calorimetry, Differential Scanning; D002626:Chemistry, Pharmaceutical; D018360:Crystallography, X-Ray; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004355:Drug Stability; D004356:Drug Storage; D004965:Estrogen Antagonists / Q000737:chemistry*; D005079:Excipients / Q000737:chemistry; D005612:Freeze Drying; D007700:Kinetics; D008055:Lipids / Q000737:chemistry*; D046529:Microscopy, Electron, Transmission; D049329:Nanostructures; D036103:Nanotechnology; D010084:Oxidation-Reduction; D010316:Particle Size; D033362:Powder Diffraction; D012995:Solubility; D012997:Solvents / Q000737:chemistry; D017550:Spectroscopy, Fourier Transform Infrared; D013501:Surface-Active Agents / Q000737:chemistry; D013629:Tamoxifen / Q000737:chemistry*; D013678:Technology, Pharmaceutical / Q000379:methods; D013696:Temperature
chemical_list: D003692:Delayed-Action Preparations; D004337:Drug Carriers; D004965:Estrogen Antagonists; D005079:Excipients; D008055:Lipids; D012997:Solvents; D013501:Surface-Active Agents; D013629:Tamoxifen
keywords: Nanostructured lipid carrier; Preformulation; Solubility; Stability; Tamoxifen